Microbot Medical (NASDAQ:MBOT) had its price objective lifted by HC Wainwright from $12.00 to $26.00 in a research note issued to investors on Monday, BenzingaRatingsTable reports. They currently have a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also commented on MBOT. Zacks Investment Research raised shares of Microbot Medical from a sell rating to a buy rating and set a $12.00 price target for the company in a research report on Wednesday, January 1st. ValuEngine lowered shares of Microbot Medical from a hold rating to a sell rating in a research report on Tuesday, December 3rd.

Shares of NASDAQ:MBOT opened at $12.65 on Monday. Microbot Medical has a fifty-two week low of $4.06 and a fifty-two week high of $20.15. The business has a 50-day simple moving average of $8.39 and a two-hundred day simple moving average of $6.27. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.29 and a current ratio of 2.29. The firm has a market cap of $82.77 million, a price-to-earnings ratio of -5.22 and a beta of 5.22.

Microbot Medical (NASDAQ:MBOT) last issued its earnings results on Thursday, November 14th. The biotechnology company reported ($0.44) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.44). As a group, research analysts predict that Microbot Medical will post -1.66 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in shares of Microbot Medical by 5.5% during the 2nd quarter. Renaissance Technologies LLC now owns 206,887 shares of the biotechnology company’s stock valued at $1,065,000 after purchasing an additional 10,838 shares during the last quarter. BlackRock Inc. increased its holdings in Microbot Medical by 5.7% in the 2nd quarter. BlackRock Inc. now owns 183,520 shares of the biotechnology company’s stock worth $945,000 after acquiring an additional 9,906 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Microbot Medical in the 2nd quarter worth approximately $45,000. Finally, Morgan Stanley increased its holdings in Microbot Medical by 77.0% in the 2nd quarter. Morgan Stanley now owns 6,316 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 2,748 shares in the last quarter. 9.77% of the stock is owned by hedge funds and other institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.

Read More: Hedge Funds Explained

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.